Literature DB >> 19306959

Hormonal contraception, sickle cell trait, and risk for venous thromboembolism among African American women.

Harland Austin1, Cathy Lally, Jane M Benson, Carolyn Whitsett, W Craig Hooper, Nigel S Key.   

Abstract

OBJECTIVE: We evaluated the effect of oral and other hormonal contraceptive (HC) use on venous thromboembolism risk among African American women and investigated whether the association was modified by the sickle cell trait. STUDY
DESIGN: We report the findings of a case-control study that included 60 African American women with an idiopathic, first episode of venous thromboembolism and 196 African American controls.
RESULTS: The odds of current HC use compared with noncurrent use contrasting cases and controls is 3.8 (95% confidence interval [CI], 1.7-8.1; P < .001). Among subjects with sickle cell trait, the odds ratio is higher (odds ratio [OR], 6.7; 95% CI, 1.0-43) than the odds ratio among subjects without sickle cell trait (OR, 2.6; 95% CI, 1.1-6.2), but the difference is not statistically significant.
CONCLUSION: This study provides persuasive evidence that hormonal contraceptive use increases venous thromboembolism risk among African American women and that the increase in risk may be larger among women with sickle cell trait.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19306959     DOI: 10.1016/j.ajog.2009.01.038

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  18 in total

1.  Framing the research agenda for sickle cell trait: building on the current understanding of clinical events and their potential implications.

Authors:  Jonathan C Goldsmith; Vence L Bonham; Clinton H Joiner; Gregory J Kato; Allan S Noonan; Martin H Steinberg
Journal:  Am J Hematol       Date:  2012-02-03       Impact factor: 10.047

2.  Impact of sickle cell trait on the thrombotic risk associated with non-O blood groups in northern Nigeria.

Authors:  Sagir G Ahmed; Modu B Kagu; Umma A Ibrahim; Audu A Bukar
Journal:  Blood Transfus       Date:  2015-05-27       Impact factor: 3.443

Review 3.  Negative health implications of sickle cell trait in high income countries: from the football field to the laboratory.

Authors:  Nigel S Key; Philippe Connes; Vimal K Derebail
Journal:  Br J Haematol       Date:  2015-03-07       Impact factor: 6.998

Review 4.  Sickle-cell trait: novel clinical significance.

Authors:  Nigel S Key; Vimal K Derebail
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2010

5.  Variant hemoglobin phenotypes may account for differential erythropoiesis-stimulating agent dosing in African-American hemodialysis patients.

Authors:  Vimal K Derebail; Patrick H Nachman; Nigel S Key; Heather Ansede; Ronald J Falk; Wayne D Rosamond; Abhijit V Kshirsagar
Journal:  Kidney Int       Date:  2011-08-17       Impact factor: 10.612

Review 6.  Pregnancy in sickle cell trait: what we do and don't know.

Authors:  Samuel Wilson; Patrick Ellsworth; Nigel S Key
Journal:  Br J Haematol       Date:  2020-02-17       Impact factor: 6.998

Review 7.  Sickle Cell Trait from a Metabolic, Renal, and Vascular Perspective: Linking History, Knowledge, and Health.

Authors:  Caroline K Thoreson; Michelle Y O'Connor; Madia Ricks; Stephanie T Chung; Anne E Sumner
Journal:  J Racial Ethn Health Disparities       Date:  2015-09

Review 8.  Sickle cell trait diagnosis: clinical and social implications.

Authors:  Rakhi P Naik; Carlton Haywood
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2015

9.  Coagulation activation in sickle cell trait: an exploratory study.

Authors:  Chirag Amin; Soheir Adam; Micah J Mooberry; Abdullah Kutlar; Ferdane Kutlar; Denise Esserman; Julia E Brittain; Kenneth I Ataga; Jen-Yea Chang; Alisa S Wolberg; Nigel S Key
Journal:  Br J Haematol       Date:  2015-09-07       Impact factor: 6.998

Review 10.  Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease.

Authors:  Esther J van Zuuren; Zbys Fedorowicz
Journal:  Cochrane Database Syst Rev       Date:  2015-12-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.